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Abstract
Background:  Coagulation problems in amyloidosis are historically associated with bleeding
tendencies (mostly Factor X abnormalities). Increased clotting was observed in isolated cases
diagnosed with low-grade disseminated intravascular coagulation (DIC). Problem of venous
thromboembolic disaease (VTD) in amyloidosis was not systematically investigated.
Methods: We evaluated frequency of VTD and risk factors for VTD in 56 consecutive amyloidosis
patients with a documented disease evaluated and followed up at our Center from 1991–2001.
Data was collected in 5 categories: (a) demographics, (b) disease and treatment, (c) thrombosis
case information, (d) major risk factors for thrombosis and (e) baseline laboratory data. Univariable
correlates of VTD were assessed using Kaplan-Meier analysis and Cox proportional hazards
analysis.
Results: Mean age of the patients was 67 (years range 21 – 83). Male/female percentage ratio was
70/30. 29 % of the patients had high creatinine level (> 1.4 mg/dl). Personal or family history of VTD
was recorded in 2 and 0 % of patients, respectively. Known hypercoagulable state was present in
1 patient (2%). 8 % of patients were smokers. Of 56 patients, 6 developed VTD (11%). Median time
from diagnosis of amyloidosis to VTD was 12.5 month (range 1–107). Treatment was given within
a median of 1 month (range 0–4) from the development of thrombosis. Only sites of VTD were
lower extremities. No cases were associated with I.V. line. 1 case (17 %) was identified
postoperatively. We identified several univariable correlates of VTD in amyloid patients, including
greater age at diagnosis (HR-2.99, P = .041), personal history of DVT (HR-47.7, P = .006) and
immobility (HR-11.78, P = .006). Presence of circulating serum M-protein had protective role in
our analysis (HR-.08, P = .031). There was no correlation with the type of treatment patients were
receiving.
Conclusion: Risk for thromboembolic diseases in patients with amyloidosis is similar to one
previously described for multiple myeloma. Additional studies with higher number of
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thromboembolic events could help to further elucidate risk factors for VTD in this population of
patients.
Background
amyloidosis is characterized by organ deposition of fibril-
lar substances of different types that have a homogeneous
eosinophilic appearance on light microscopy [1,2]. The
diagnosis is confirmed by demonstration of an apple-
green birefringence under polarized light of specimens
stained with Congo red. Primary amyloidosis (AL) should
be considered in any patient who has a monoclonal pro-
tein in the serum or urine and refractory congestive heart
failure, nephrotic syndrome, sensorimotor peripheral
neuropathy, carpal tunnel syndrome, orthostatic hypo-
tension, or steatorrhea. At diagnosis, approximately one-
third have nephrotic syndrome, one-fifth have carpal tun-
nel syndrome, one-fourth have congestive heart failure,
and about 15% have peripheral neuropathy [1,2].
Bleeding problems due to vascular deposition of amyloid
resulting in vascular fragility, deficiencies of clotting fac-
tors (particularly Factor X) or enhanced fibrinolytic activ-
ity often complicate this disease [3]. Acquired deficiency
of Factor X is the most common coagulation factor defi-
ciency identified in patients with amyloidosis [4]. Throm-
bosis, although less common, also can occur. Some case
reports described thromboembolic complications of amy-
loidosis [5,6]. Association of nephrotic syndrome, well-
documented complication of systemic amyloidosis, and
renal vein thrombosis are well documented [7,8]. Cardiac
amyloidosis produces cases of atrial electromechanical
dissociation with resulting atrial arrhythmias and forma-
tion of atrial clots [9]. Various pathogenic factors have
been proposed to explain abnormal hemostasis in
patients with amyloidosis. Recently, impairment of the
thrombin-antithrombin pathway, in association with the
low antithrombin biological activity was recognized to
have possible pathogenic role in hypercoagulability of
amyloidosis patients [10].
However, the problem of venous thromboembolic dis-
ease (VTD) in this disease was not systematically investi-
gated. We evaluated the frequency of VTD and risk factors
for VTD in 56 consecutive amyloidosis patients with a
documented disease evaluated and followed up at our
Center from 1991–2001.
Methods
We reviewed complete medical records of all patients with
amyloidosis who were prospectively entered in the data-
base. Fifty-six patients were identified. They were evalu-
ated and followed up by staff oncologists in the
Department of Hematology and Oncology, Myeloma
Research Program at the Cleveland Clinic Foundation in
the period 1991–2001.
The Cleveland Clinic Foundation (CCF) is an urban terti-
ary referral center and a teaching hospital. Our proposal
was submitted to the CCF Institutional Review Board, and
we were granted approval, based on an expedited review.
The requirement for obtaining informed consent was
waived based on the study designs (standard medical
record based review) and patient anonymity. The study
did not require any third party funding.
The patients' computerized inpatient and outpatient med-
ical records were initially reviewed by one of the co-inves-
tigators (CMG). Additional review was done
independently by a second co-investigator (SG). If elec-
tronic data were incomplete, the hard copies of charts
were also reviewed. When necessary, missing information
was sought from referring providers. However, in a
number of cases, this was unavailable.
All cases of VTD of extremities were diagnosed by Duplex
ultrasound. Term immobility was used for patients who
were hospitalized or bed bound for more than 7 days at
the time of VTD diagnosis.
Personal history of VTD was defined as a history of docu-
mented thromboembolism prior to the diagnosis of PCD.
Patients were screened for a hypercoagulable state only
when they developed what appeared to be a vascular event
that needed further investigation.
Data was collected in 5 categories: (a) demographics, (b)
disease and treatment, (c) thrombosis case information,
(d) major risk factors for thrombosis and (e) baseline lab-
oratory data. Data were manually recorded onto
researcher-developed data collection forms and subse-
quently entered into a computerized database.
Statistical analysis
Categorical variables are summarized as frequencies and
percentages and continuous variables as the mean, stand-
ard deviation, median, and range. Time until develop-
ment of a VTD was estimated using the Kaplan-Meier
method. Follow-up was calculated from the date of diag-
nosis to the date of either the first VTD or the date of final
follow-up visit. Cox proportional hazards analysis was
used to identify univariable correlates of thromboembolic
event. If Cox analysis could not be done due to lack of var-
iability, then the log-rank test was performed instead.International Seminars in Surgical Oncology 2005, 2:17 http://www.issoonline.com/content/2/1/17
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There were 8 possible risk factors for VTD: personal and
family history of VTD, known hypercoagulable state, non-
plasma cells related concomitant neoplasm's, immobility,
estrogen treatment, smoking, and use of indwelling cath-
eters at any time from initial diagnosis.
All statistical analyses were two-sided; P < 0.05 was used
to indicate statistical significance. Analyses were per-
formed using SAS® software, version 6.12.
Results
Patients' characteristics
Data was available on 56 patients (Table 1.). 50 (89%)
had primary amyloidosis (AL), 1 (2%) had kappa light
chain disease, and in 5 (9%) patients type could not be
identified. One patient had both AL and familial amy-
loidosis. 37 (66%) had confirmed cardiac involvement by
biopsy or alternatively, typical findings on Echocardio-
gram. Confirmed (biopsy) renal involvement was found
in 18 (32%) of patients. Localized amyloidosis was iden-
tified in 6 (11%) of patients. Two cases were pulmonary,
2 gastrointestinal, and one case was localized to skin and
genitourinary tract, respectively. 39 (70%) were men and
17 (30%) were women. Average age was 67 years (range
21 – 83). Of the heavy chain types found in patients, 75%
were IgG, 17% IgA, 1% IgM. 44/56 (78.5%) of patients
did not have heavy chain M-protein in the serum.
The light chain was lambda (λ) in 18 (32% of all patients)
and kappa (κ) in 7 patients (13%). The remainder did not
have identifiable light chain (31, 55%). All patients had
amyloid deposits by Congo Red stain. The bone marrow
biopsy results were available in 53 patients (95%) at the
time of diagnosis. The median percentage of bone marrow
occupied by plasma cells was 5% (range 0.0 – 50%).
Serum creatinine level was elevated in 29% of all patients.
Albumin was low (< 3.5 gm/dl) in 45% patients overall.
Beta-2-microglobulin was high (>1.9) in the majority of
patients (70%). Bone survey was negative for lytic lesions
in all cases.
Out of 56 patients with amyloidosis, 1 (2%) patients had
personal and no one had family history of thromboembo-
lism. 1/56 were diagnosed with hypercoagulable state
(antithrombin deficiency). Patients were treated with
multiple regimens that included: steroids (36%), α-inter-
feron (23%), vincristine (16%), liposomal doxorubicin
(16%), melphalan (9%), thalidomide (2%) and rituxi-
mab (2%).
The five different drug combinations used in the treat-
ment of amyloid patients are presented in Table 2. No
patients were treated with high-dose chemotherapy with
peripheral stem cell support (HDC-PSC).
Table 1: Clinical characteristics of amyloidosis patients at 
presentation (N = 56)
Characteristics
Male/Female 39/17
Age (years)
Median 67
Range (21–83)
Serum M-Protein (g/L)1 (N = 18)
Mean 0.5
Median 0.2
Range (0–4.0)
24-hour Urine Protein (g)1 (N = 47)
Mean 3.2
Median 0.4
Range (0–26.9)
BMPC* (%)2 (N = 53)
Mean 8
Median 5
Range (0–50)
B2 Microglobulin (mg/dl)1 (N = 47)
Mean 3.4
Median 2.7
Range (0.3–18.4)
Serum albumin (g/L)1 (N = 53)
Mean 3.4
Median 3.6
Range (1.0–5.4)
Immunoglobulin type Heavy Chain (N = 12)
IgA (%) 2 (17)
IgG (%) 9 (75)
IgM (%) 1 (8)
Unknown 0
Light Chain (N = 25)
λ 18 (72)
κ 7 (28)
History of VTD Personal
Yes (%) 1 (2)
No (%) 53 (94)
Unknown (%) 2 (4)
Family
No (%) 52 (93)
Unknown (%) 4 (7)
1 CCF Laboratory reference range, normal values:
Serum M-protein: 0 g/dl
Urine Protein: 0–0.15 g/24°
β2 Macroglobulin: 0.3–1.9 mg/dl
Serum Albumin: 3.5–5.0 g/L
2 Bone Marrow Plasma CellsInternational Seminars in Surgical Oncology 2005, 2:17 http://www.issoonline.com/content/2/1/17
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Patients with VTD
Cases of thromboembolism were diagnosed by Duplex
ultrasound. There was no evidence of pulmonary embo-
lism or atrial clots in this group of patients. Of 56 patients
reported in this paper 6 (11%) had one or more episodes
of symptomatic, objectively documented VTD after the
diagnosis of amyloidosis (Table 3). All cases were of lower
extremities. The time from diagnosis to development of
VTD was 12.5 months (range 1–107). Median time from
last treatment to VTD event was 1 month (0–4). Out of 6
patients with VTD 17% (1 case) had a personal history of
thromboembolism. No patients with VTD had a history of
hypercoagulable state, smoking, or oral estrogen use. Four
(67%) patients with VTD had prolonged immobility and
1 (17%) had indwelling catheter at some point during the
disease. One patient (17%) developed VTD within 6
weeks from surgery.
Univariable correlates of VTD in amyloidosis patients are
presented in Table 4. A large number of factors were
entered into the model including the following: gender,
age at diagnosis, immunoglobulin type, personal history
of VTD, hypercoagulable state, non-plasma cell related
concomitant neoplasms, smoking, immobility, indwell-
ing catheters, estrogen treatment, percentage of plasma
cells in the bone marrow biopsy, creatinine level, cor-
rected serum calcium level, serum albumin, white blood
cells and platelet count, hemoglobin level, β 2-microglob-
ulin, serum M protein level, 24 hour urine protein level,
as well as individual agents and combination of chemo-
therapeutic agents.
Among these, personal history of VTD (HR-47.7; P = .006,
CI-2.98–766), immobility (HR-11.78; P = .006, CI-2.02–
68.8), absence of measurable M-protein (HR-12.5; P =
.031, CI-1.25–100), and age at diagnosis (HR-2.99, P =
.041, CI-1.05–8.56) were identified as univariable corre-
Table 2: Combination chemotherapies used in the treatment of 
amyloidosis
Type of Treatment N %
HD steroids1 20 36
DVd2 91 6
MP3 58
CP4 12
TD5 12
N – Number of patients
% – Percentage of patients treated with particular regimen
1 High-dose Dexamethasone
2 Doxil®, Vincristine, Dexamethasone
3 Melphalan, Prednisone
4 Cytoxan, Prednisone
5 Thalidomide, Dexamethasone
Table 3: Clinical characteristics of amyloidosis (N = 6) patients 
with VTD
Characteristics
Male/Female 4/2
History of VTD
Personal
Yes 1
No 5
Family
No 6
Serum M-Protein1
None 3
Yes 2
Unknown 1
24-hour Urine Protein1
<0.15 gr 3
>0.15 gr 2
Unknown 1
BMPC2
≤ 5% 3
> 5% 1
Unknown 2
B2 Microglobulin1
< 1.9 mg/L 1
> 1.9 mg/L 4
Unknown 1
Serum albumin1
< 3.5 g/L 3
3.5 – 5.0 g/L 3
Immunoglobulin type
None 4
IgG 1
IgM 1
None 4
κ 2
WBC count
4 – 11 × 106/L 6
Platelet count
150 – 400 × 106/L 6
1CCF Laboratory reference range, normal values:
Serum M-protein: 0 g/dl
Urine Protein: 0–0.15 g/24°
β2 Macroglobulin: 0.3–1.9 g/dl
Serum Albumin: 3.5–5.0 g/L
2 Bone Marrow Plasma CellsInternational Seminars in Surgical Oncology 2005, 2:17 http://www.issoonline.com/content/2/1/17
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lates of VTD in amyloidosis patients (Table 4.) Multivari-
able analysis could not be done due to low number of
events.
Discussion
This study shows increased incidence of VTD (11% at 10
years review) in amyloidosis patients as compared to the
general population (0.1% per person/per year) [11]. This
is similar to frequency of VTD found in multiple myeloma
(MM) (10%) [12], and slightly higher than in patients
with monoclonal gammopathy with undetermined signif-
icance (MGUS) (7.5%) [12]. Previously, only case reports
of thromboembolism in patients with amyloidosis were
presented in the literature [5,6,9,13].
Studies presented herein have significant limitations. It is
highly dependent on the quality of historical data.
Absence of a potential risk factor or patient characteristics
in the medical records is assumed to mean that the factor
is absent. The statistical analysis is limited by the fact that
several of the variables that were considered as correlates
of VTD were not baseline characteristics. Ideally, these var-
iables would be analyzed as time-dependent covariates.
However, timing of these variables was not known. It is
only known that they occurred before development of the
event in patients with VTD or before the last follow-up
among patients who did not develop VTD yet.
Results of the study presented herein point to strong cor-
relation between some of the established risk factors for
VTD (personal history and immobility) and thromboem-
bolic events in patients with amyloidosis. Other well-
known VTD risk factors (estrogen use, concomitant solid
malignancies, and use of indwelling catheters) did not
seem to be of importance in our patients.
Data about family history of VTD is missing in more than
10% of patients. Additionally, existing data seem to be
inadequate. From available records it seems that none of
the 56 patients had a family history of VTD. Although this
could be due to the low number of patients a more prob-
able explanation is poor history taking. Therefore; family
history was not included in univariable analysis. Types of
treatment (individual drugs or chemotherapy combina-
tions) do not correlate with VTD. It is important to men-
tion that none of the patients included in this study had
treatment with high dose chemotherapy and stem cell
support.
One of the univariable correlates of VTD identified in our
group of amyloidosis patients is increased age. Risk of
VTD in these patients is increasing 3 times with every 10-
year increase in age. A number of studies support an asso-
ciation between increasing age and a higher incidence of
venous thromboembolism [14-16]. Patients over age 40
are at a significantly increased risk compared with
younger patients [17]. Risk continues to increase with
increasing age, approximately doubling with each decade
after age of 40 [18].
It seems that in our amyloidosis patients, VTD age risk is
in excess of that seen in general population. It does not
seem that this increased risk correlates with more aggres-
sive disease, since age was not found to be an important
prognostic factor for survival in primary systemic amy-
loidosis in multiple studies [19-21]. However, other types,
such as senile with normal transthyretin (ATTR), amy-
loidosis associated with Alzheimer's disease (Aβ), and
islet amyloid polypeptide deposits (AIAPP) are very
strongly associated with both old age and the aging
process.
Another significant risk factor of VTD in our patients was
absence of circulating monoclonal protein. This is a char-
acteristic for types of disease other than primary amy-
loidosis (AL) including secondary (AA), familial with
genetically variant transthyretin (ATTR), amyloidosis
associated with dialysis (Aβ2M), as well as Aβ and AIAPP
forms. Again, these results point to possible increase inci-
dence of VTD in the forms other than primary.
Human serum amyloid A (SAA) is a precursor protein in
inflammation-associated secondary amyloidosis (AA). It
could interfere with the coagulation process through
interaction with heparin/heparan sulfate at the specific
binding site (C-terminal residue 78 to 104) [22]. SAA also
seems to play a role in atherogenesis, as well as in throm-
bus formation at the vascular injury site [23,24]. Second-
ary amyloidosis (AA) is manifested in patients with
underlying chronic inflammation (rheumatoid arthritis,
ankylosing spondylitis, inflammatory bowel disease,
tuberculosis, osteomyelitis, Familial Mediterranean
Fever) [25-27]. It is driven by different cytokines, includ-
Table 4: Identifying univariable correlates of VTD in amyloidosis 
(N-56)
Variable (Reference)
HR2 95% CI2 P1
Age at Diagnosis (per 10 year increase) 2.99 1.05–8.56 0.0411
Personal History of VTD (Yes/No) 47.7 2.98–766 0.0061
Immobile (Yes/No) 11.78 2.02–68.8 0.0061
Serum M-protein
Per 1 mg/dl increase 0.43 0.05–3.70 0.45
Normal/Abnormal 12.5 1.25–100 0.0311
1 significant (P < 0.05)
2 HR – Hazard Ratio; CI – Confidence IntervalInternational Seminars in Surgical Oncology 2005, 2:17 http://www.issoonline.com/content/2/1/17
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ing tumor necrosis factor (TNF-α), interleukin-6 (IL-6),
and interleukin-1 (IL-1) [28]. IL-6 was found to promote
coagulation without affecting fibrinolysis [29]. It activates
coagulation cascade through tissue factor stimulation and
increased transcription of factor VIII, up regulates tran-
scription of fibrinogen, increases von Willebrand's factor,
and decreases protein S [29]. Is there any correlation
between SAA or any other circulating non-monoclonal
protein precursors of amyloid and VTD will have to be
elucidated in future studies. It is still uncertain if proposed
increased incidence of thromboembolism is the result of
the very process of deposition of the abnormally folded
protein outside cells, consequential organ damage, or
alternatively, underlying processes leading to amyloid
deposits. However, it does not seem to be related to the
type of treatment used in this disease. This is in accord-
ance with our own findings in the patients with multiple
myeloma and MGUS [12].
Conclusion
Our analysis confirmed that well-known risk factors for
thromboembolism including personal history of VTD and
immobilization could represent confounding factors in
amyloidosis patients, too. However, additional correlates
have to be considered, including type of disease and
patients' age.
In our opinion, these patients need to be closely moni-
tored for development of VTD. Standard thromboembolic
prophylaxis should be used with extreme caution, consid-
ering bleeding tendency in the patients with amyloidosis.
In our opinion development of prospective studies deal-
ing with venous thromboembolism in amyloidosis
patients is of utmost importance. We will need to define
pathophysiological mechanisms responsible in order to
employ the most effective prophylactic measures.
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